[go: up one dir, main page]

AR048537A1 - Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. - Google Patents

Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.

Info

Publication number
AR048537A1
AR048537A1 ARP050101393A ARP050101393A AR048537A1 AR 048537 A1 AR048537 A1 AR 048537A1 AR P050101393 A ARP050101393 A AR P050101393A AR P050101393 A ARP050101393 A AR P050101393A AR 048537 A1 AR048537 A1 AR 048537A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
group
amino
heteroaryl
Prior art date
Application number
ARP050101393A
Other languages
English (en)
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of AR048537A1 publication Critical patent/AR048537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Derivados de nucleosidos y composiciones farmacéuticas que los contienen Reivindicacion 1: Un compuesto caracterizado porque presenta la siguiente formula (1): donde : W, W1 y W2 se seleccionan independientemente del grupo que connsiste en H y una prodroga aceptable para uso farmacéutico; R se selecciona del grupo que consiste en H o (C1-3)alquilo; R1 se selecciona del grupo que consiste en H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo y alquinilo sustituido; Y es un enlace, -CH2- o -O-; Y1 se selecciona deln grupo que consiste en H, halo, hidroxilo, tioalquilo, amino y amino sustituido; Z se selecciona del grupo que consiste en acilo, ciano, carboxilo, éster carboxílico, -C(O)NR20R21, halo, -B(OH)2, - C(=NR2)R3, nitro, alquenilo, alquenilo sustituido, acetilenilo y acetilenilo sustituido de formula -C:::C-R4; donde R2 se selecciona del grupo que consiste en H, -OH, -OR5 amino, amino sustituido, y (C1-2)alquilo, donde R5 se selecciona del grupo que consiste en alquilo y alquilo sustituido; R3 se selecciona del grupo que consiste en H, alquilo, alquilo sustituido, amino y amino sustituido; R4 se selecciona del grupo que consiste en H, fenilo, fenilo sustituido, heteroarilo, heteroarilo sustituido, -Si(R8)3, carboxilo, ésteres carboxílicos y -C(O)NR6R7, donde R6 y R7 son independientemente H, alquilo, o R6 y R7, junto con el átomo de N al que están unidos, están combinados para formar un grupo heterocíclico, heterocíclico sustituido, heteroarilo o heteroarilo sustituido; cada R8 es independientemente (C1- 4)alquilo o fenilo, y R20 y R21 son independientemente H, alquilo, alquilo sustituido,arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo y heterociclo sustituido, o R20 y R21, junto con el átomo de N al que están unidos, forman un grupo heterocíclico o heterocíclico sustituido; o sales de éstos aceptables para el uso farmacéutico.
ARP050101393A 2004-04-08 2005-04-08 Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. AR048537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/821,638 US7094768B2 (en) 2002-09-30 2004-04-08 Nucleoside derivatives for treating hepatitis C virus infection

Publications (1)

Publication Number Publication Date
AR048537A1 true AR048537A1 (es) 2006-05-03

Family

ID=36603341

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101393A AR048537A1 (es) 2004-04-08 2005-04-08 Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.

Country Status (7)

Country Link
US (3) US7094768B2 (es)
EP (1) EP1776376A2 (es)
AR (1) AR048537A1 (es)
AU (1) AU2005324476A1 (es)
CA (1) CA2562224A1 (es)
TW (1) TW200602064A (es)
WO (1) WO2006075993A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822563B2 (en) 1997-09-22 2004-11-23 Donnelly Corporation Vehicle imaging system with accessory control
US5877897A (en) 1993-02-26 1999-03-02 Donnelly Corporation Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array
US6891563B2 (en) 1996-05-22 2005-05-10 Donnelly Corporation Vehicular vision system
US7655894B2 (en) 1996-03-25 2010-02-02 Donnelly Corporation Vehicular image sensing system
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
WO2003093857A2 (en) 2002-05-03 2003-11-13 Donnelly Corporation Object detection system for vehicle
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
EA200500584A1 (ru) * 2002-09-30 2006-02-24 Дженелэбс Текнолоджиз, Инк. Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
US7824851B2 (en) * 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
KR20050109918A (ko) * 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
US7151089B2 (en) * 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
KR20060096487A (ko) * 2003-10-27 2006-09-11 진랩스 테크놀러지스, 인크. 바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
AU2004295291A1 (en) * 2003-10-27 2005-06-16 Smithkline Beecham Corporation Nucleoside compounds for treating viral infections
US7526103B2 (en) 2004-04-15 2009-04-28 Donnelly Corporation Imaging system for vehicle
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7972045B2 (en) 2006-08-11 2011-07-05 Donnelly Corporation Automatic headlamp control system
US8013780B2 (en) 2007-01-25 2011-09-06 Magna Electronics Inc. Radar sensing system for vehicle
CN101835374B (zh) 2007-07-09 2014-08-27 东弗吉尼亚医学院 具有抗病毒和抗微生物性质的取代的核苷衍生物
US7914187B2 (en) 2007-07-12 2011-03-29 Magna Electronics Inc. Automatic lighting system with adaptive alignment function
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
KR101735134B1 (ko) 2009-07-27 2017-05-24 마그나 일렉트로닉스 인크. 주차 보조 시스템
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
SG188497A1 (en) * 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
US9085261B2 (en) 2011-01-26 2015-07-21 Magna Electronics Inc. Rear vision system with trailer angle detection
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
AU2013344757A1 (en) * 2012-11-19 2015-05-21 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
US10160382B2 (en) 2014-02-04 2018-12-25 Magna Electronics Inc. Trailer backup assist system
CA2937548C (en) 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10078789B2 (en) 2015-07-17 2018-09-18 Magna Electronics Inc. Vehicle parking assist system with vision-based parking space detection
EP3331895B1 (en) 2015-08-06 2020-07-29 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
WO2021226521A1 (en) * 2020-05-07 2021-11-11 Abraham Edward H Systems and methods for use of adenosine triphosphate (atp) to relieve symptoms of covid-19 and related infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
WO1993016094A2 (en) * 1992-02-12 1993-08-19 Chromagen, Inc. Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
DK62592D0 (es) * 1992-05-14 1992-05-14 Novo Nordisk As
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
AU690587B2 (en) 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
EP0679657B1 (de) * 1994-04-27 2003-07-09 Novartis AG Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US6211154B1 (en) * 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6703394B2 (en) * 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US6090937A (en) * 1998-03-17 2000-07-18 Ajinomoto Co., Inc. Methods for producing nucleoside derivatives and intermediates therefor
CA2326535A1 (en) * 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6763167B2 (en) * 2000-12-20 2004-07-13 Polaroid Corporation Integral organic light emitting diode fiber optic printhead
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
EA200500584A1 (ru) 2002-09-30 2006-02-24 Дженелэбс Текнолоджиз, Инк. Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
WO2004065398A2 (en) 2003-01-15 2004-08-05 Ribapharm Inc. Synthesis and use of 2'-substituted-n6-modified nucleosides

Also Published As

Publication number Publication date
US7432248B2 (en) 2008-10-07
CA2562224A1 (en) 2006-07-20
WO2006075993A2 (en) 2006-07-20
US7629328B2 (en) 2009-12-08
AU2005324476A1 (en) 2006-07-20
WO2006075993A3 (en) 2006-10-26
US20060258613A1 (en) 2006-11-16
US20050119200A1 (en) 2005-06-02
EP1776376A2 (en) 2007-04-25
US7094768B2 (en) 2006-08-22
TW200602064A (en) 2006-01-16
US20090036399A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
AR048537A1 (es) Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR045938A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
JP2019507774A5 (es)
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR104214A1 (es) Amidas cíclicas sustituidas como herbicidas
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
AR054799A1 (es) Derivados de oxindol
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR063213A1 (es) Amidas azociclicas fungicidas, composiciones fungicidas que las comprenden y su empleo en un metodo para controlar enfermedades en las plantas causadas por patogenos fungicos de la clase de los oomycetes.
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR064657A1 (es) 8- alquinilxantinas y derivados
PE20230251A1 (es) Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
AR035230A1 (es) Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
PE20220252A1 (es) Compuestos de pirrol
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы

Legal Events

Date Code Title Description
FB Suspension of granting procedure